Jazz Pharmaceuticals on Feb. 3 announced the acquisition of GW Pharmaceuticals for a total consideration of $7.
Leerink Swann’s healthcare analysts came out today with favorable reports on pharmaceutical giants Gilead Sciences, Inc. (NASDAQ:GILD) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ).
Cantor analyst Irina Rivkind was out today pounding the table on Jazz Pharmaceuticals (NASDAQ:JAZZ) Monday, reiterating a Hold rating and a price target of $195. …
In a research report issued today, Cantor analyst Irina Rivkind assigned a Hold rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and raised her price target to …
In a research report issued Friday, Canaccord Genuity analyst John Newman reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a $163 price target, …
In a research note released yesterday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Jazz Pharmaceuticals (JAZZ) with a $151 price …
